N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Coherex Medical (Salt Lake City, UT) a development-stage medical device company focused on the Flatstent™ EF PFO Closure System used to close patent foramen ovale heart defects, closed a $16.5M Series B financing. Participants include Oxford Bioscience Partners, vSpring Capital and Tullis Health Investors.

Catheter Connections ( Park City, UT) an early-stage focused on accessory products for the prevention of infection in the vascular catheter access device market, closed a $1.3M Series A financing. Participants include vSpring Capital and Kickstart Seed Fund.

miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.

Control Medical Technology (Park City, UT) a medical device company mechanical, rotational vacuum assisted and ergonomic improvements of single-handed fluid, pathology, and tissue aspirator, closed a $3M Series A financing. Participants include Spring Bay Ventures.
*Estimated capital raise

Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development, closed a $145M Series A financing. Participants include Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments.

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.

CeraPedics (Broomfield, CO) a clinical stage device company focused on osteobiologic products for bony voids, closed a $15M Series B financing. Participants include NGN Capital and OrbiMed Advisors.

BiOptix (Boulder, CO) a commercial focused developer of an array-based biomolecule detection system that addresses many markets that currently cannot obtain the needed sensitivity and throughput in a single solution, closed a $3M Series A finacing. Participants include Boulder Ventures.